1. Previous history of Tuberculosis or known active Mycobacterium tuberculosis infection <br/ >2. Received BCG vaccine within one year prior to screening <br/ >3. Fever (greater than or equal to 38 ºC/100.4°F) or any other respiratory symptoms/illnesses within the past 14 days <br/ >4. Pregnant or lactating women <br/ >5. Women of child-bearing potential not agreeing to use adequate contraception <br/ >6. Current active viral or bacterial infection <br/ >7. Expected vaccination during the study period, independently of the type of vaccination <br/ >8. Severely immunocompromised subjects. <br/ >9. Active solid or non-solid malignancy or lymphoma within the prior two years <br/ >10. Individuals known to be hypersensitive to any component of the vaccine <br/ >11. Eczema or other significant skin lesion or infection at the site/s of injection. <br/ >12. Any other medical condition which in the opinion of the investigator may affect the subjectâ??s safety or study participation and conduct <br/ >

1. Previous history of Tuberculosis or known active Mycobacterium tuberculosis infection <br/ >2. Received BCG vaccine within one year prior to screening <br/ >3. Fever (greater than or equal to 38 ºC/100.4°F) or any other respiratory symptoms/illnesses within the past 14 days <br/ >4. Pregnant or lactating women <br/ >5. Women of child-bearing potential not agreeing to use adequate contraception <br/ >6. Current active viral or bacterial infection <br/ >7. Expected vaccination during the study period, independently of the type of vaccination <br/ >8. Severely immunocompromised subjects. <br/ >9. Active solid or non-solid malignancy or lymphoma within the prior two years <br/ >10. Individuals known to be hypersensitive to any component of the vaccine <br/ >11. Eczema or other significant skin lesion or infection at the site/s of injection. <br/ >12. Any other medical condition which in the opinion of the investigator may affect the subjectâ??s safety or study participation and conduct <br/ >

N/A

N/A

1. Previous history of Tuberculosis or known active Mycobacterium tuberculosis infection <br/ >2. Received BCG vaccine within one year prior to screening <br/ >3. Fever (greater than or equal to 38 ºC/100.4°F) or any other respiratory symptoms/illnesses within the past 14 days <br/ >4. Pregnant or lactating women <br/ >5. Women of child-bearing potential not agreeing to use adequate contraception <br/ >6. Current active viral or bacterial infection <br/ >7. Expected vaccination during the study period, independently of the type of vaccination <br/ >8. Severely immunocompromised subjects. <br/ >9. Active solid or non-solid malignancy or lymphoma within the prior two years <br/ >10. Individuals known to be hypersensitive to any component of the vaccine <br/ >11. Eczema or other significant skin lesion or infection at the site/s of injection. <br/ >12. Any other medical condition which in the opinion of the investigator may affect the subjectâ??s safety or study participation and conduct <br/ >

1. Previous history of Tuberculosis or known active Mycobacterium tuberculosis infection <br/ >2. Received BCG vaccine within one year prior to screening <br/ >3. Fever (greater than or equal to 38 ºC/100.4°F) or any other respiratory symptoms/illnesses within the past 14 days <br/ >4. Pregnant or lactating women <br/ >5. Women of child-bearing potential not agreeing to use adequate contraception <br/ >6. Current active viral or bacterial infection <br/ >7. Expected vaccination during the study period, independently of the type of vaccination <br/ >8. Severely immunocompromised subjects. <br/ >9. Active solid or non-solid malignancy or lymphoma within the prior two years <br/ >10. Individuals known to be hypersensitive to any component of the vaccine <br/ >11. Eczema or other significant skin lesion or infection at the site/s of injection. <br/ >12. Any other medical condition which in the opinion of the investigator may affect the subjectâ??s safety or study participation and conduct <br/ >